Evidence map›Paper›PMID 35584623›Full record

Trial reportCell reports. Medicine2022

Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults.

Anurag Singh, Davide D'Amico, Pénélope A Andreux, Andréane M Fouassier, William Blanco-Bose, Mal Evans, Patrick Aebischer, Johan Auwerx, Chris Rinsch

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cell reports. Medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03464500 (A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy of AMAZ-02 on Muscle Function in Otherwise Healthy Middle-aged, Overweight and Inactive Individuals), which is not on this map. Cited by 183 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
183citing papers in PubMed, 3 pooled it
19.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03464500 nacompletednot on this map

A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy of AMAZ-02 on Muscle Function in Otherwise Healthy Middle-aged, Overweight and Inactive Individuals

TypeinterventionalSponsorAmazentis SARan2018 to 2019Enrolled90ConditionsMuscle Function, Mitochondrial Function, Overweight, Healthy AgingArmsMitopure 500mg, Mitopure 1000mg, Placebo
3 · Its place in the literature

Who cites it

183 citing papers in PubMed, 3 syntheses or guidelines pooled it, 195 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Bone health: biology and nutrition.Current opinion in clinical nutrition and metabolic care · 2024
    Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Review
  9. Article
  10. Review
  11. Article
  12. The Hallmarks of Aging: From Molecular Mechanisms to Clinical Translation.International journal of molecular sciences · 2026
    Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review

123 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Anurag SinghAmazentis SA, EPFL Innovation Park, Bâtiment C, 1015 Lausanne, Switzerland. Electronic address: asingh@amazentis.com.
Davide D'AmicoAmazentis SA, EPFL Innovation Park, Bâtiment C, 1015 Lausanne, Switzerland.
Pénélope A AndreuxAmazentis SA, EPFL Innovation Park, Bâtiment C, 1015 Lausanne, Switzerland.
Andréane M FouassierAmazentis SA, EPFL Innovation Park, Bâtiment C, 1015 Lausanne, Switzerland.
William Blanco-BoseAmazentis SA, EPFL Innovation Park, Bâtiment C, 1015 Lausanne, Switzerland.
Mal EvansKGK Science, 255 Queens Avenue #1440, London, ON N6A 5R8, Canada.
Patrick AebischerEcole Polytechnique Fédérale de Lausanne, 1015 Lausanne, Switzerland.
Johan AuwerxLaboratory of Integrative Systems Physiology, Ecole Polytechnique Fédérale de Lausanne, 1015 Lausanne, Switzerland.
Chris RinschAmazentis SA, EPFL Innovation Park, Bâtiment C, 1015 Lausanne, Switzerland.
Amazentis (Switzerland) · CHÉcole Polytechnique Fédérale de Lausanne · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Targeting mitophagy to activate the recycling of faulty mitochondria during aging is a strategy to mitigate muscle decline. We present results from a randomized, placebo-controlled trial in middle-aged adults where we administer a postbiotic compound Urolithin A (Mitopure), a known mitophagy activator, at two doses for 4 months (NCT03464500). The data show significant improvements in muscle strength (∼12%) with intake of Urolithin A. We observe clinically meaningful improvements with Urolithin A on aerobic endurance (peak oxygen oxygen consumption [VO

Indexed as

MitophagyMuscle StrengthBiomarkersCoumarinsHumansMiddle AgedMitochondria3,8-dihydroxy-6H-dibenzo(b,d)pyran-6-oneBiomarkersCoumarinsagingclinical trialexercise performancemitochondriamitophagyMitopuremuscle strengthUrolithin A

Identifiers

PMID35584623
PMCPMC9133463
OpenAlexW4280515185

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.